The oncogenic receptor tyrosine kinases are key to lung cancer malignant transformation, as evidenced by the clinical successes of EGFR, MET, and EML4-ALK inhibition by small molecule therapeutics [7,8]. The gene discussed is EML4; the disease is lung cancer.